Clinical Trials Logo

Peripartum Cardiomyopathy clinical trials

View clinical trials related to Peripartum Cardiomyopathy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04143997 Withdrawn - Clinical trials for Diastolic Dysfunction

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

Start date: November 1, 2019
Phase:
Study type: Observational

The purpose of this project is to evaluate parameters of diastolic dysfunction assessed by clinical echocardiogram in patients who have had recovery of systolic function.

NCT ID: NCT02590601 Withdrawn - Clinical trials for Peripartum Cardiomyopathy

Bromocriptine in the Treatment of Peripartum Cardiomyopathy

BRO-HF
Start date: January 1, 2017
Phase: Phase 3
Study type: Interventional

Peripartum cardiomyopathy (PPCM) is a rare, but significant heart disease affecting young women in the puerperal period. Thus far, no specific treatment has been approved to treat this disease. PPCM has a wide spectrum of clinical manifestations ranging from mild heart failure to severe cardiomyopathy, cardiogenic shock and death. A significant proportion of survivors have persistent chronic heart failure leading to disabling symptoms and decreased quality of life. Animal studies have suggested that prolactin is central to the development of PPCM. Prolactin has pro-inflammatory and anti-angiogenic effects that may promote PPCM. Bromocriptine, a central dopamine agonist known to decrease prolactin levels, might thwart its deleterious effects in women suffering from PPCM. Following this rationale, bromocriptine should improve myocardial function in women suffering from PPCM and thus, improve cardiovascular outcomes and healthcare outcomes.